Transcriptome Analysis of Combined Radiotherapy and YM101(a novel bispecific antibody that targets TGF-beta and PD-L1) Treatment.

This RNA sequencing study investigates transcriptional changes in 4T1 breast tumor tissues following combined radiotherapy (RT) and YM101 (an anti-TGF-beta/PD-L1 bispecific antibody) treatment. The analysis aims to understand the molecular mechanisms underlying the synergistic effects of RT and immunotherapy, focusing on immune response modulation and tumor microenvironment remodeling. The dataset includes transcriptome profiles from four treatment groups: control, RT alone, YM101 alone, and RT+YM101 combination, providing insights into therapeutic resistance mechanisms and potential strategies for enhancing antitumor immunity.